Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.42
-0.38 (-0.48%)
Streaming Delayed Price
Updated: 2:06 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
53
54
Next >
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
June 12, 2023
For the bull run to continue we need broader market participation from SMID caps.
Via
Talk Markets
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
June 12, 2023
From
AstraZeneca
Via
Business Wire
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e
Via
Benzinga
Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories
June 09, 2023
Financial Times
Via
Benzinga
This Is What Whales Are Betting On AstraZeneca
June 07, 2023
Via
Benzinga
$100 Invested In AstraZeneca 10 Years Ago Would Be Worth This Much Today
June 05, 2023
Via
Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
June 09, 2023
AstraZeneca Plc (NASDAQ: AZN)
Via
Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
June 09, 2023
AstraZeneca plc (NASDAQ: AZN) has entered into a
Via
Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t
Via
Benzinga
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
June 07, 2023
Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a
Via
Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
June 05, 2023
Via
Benzinga
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
June 05, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
June 05, 2023
From
AstraZeneca
Via
Business Wire
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 05, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
June 04, 2023
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
June 03, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
June 02, 2023
From
AstraZeneca
Via
Business Wire
3 Nasdaq 100 Stocks That Are Surefire Buys in June
June 02, 2023
These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.
Via
The Motley Fool
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
June 01, 2023
From
AstraZeneca
Via
Business Wire
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
May 30, 2023
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.
Via
Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
May 30, 2023
A surge in price for shares of Nvidia Corporation (NASDAQ: NVDA) after the company’s quarterly earnings results and guidance has put the semiconductor company in the elusive $1 trillion market...
Via
Benzinga
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
May 28, 2023
These two pharmaceutical companies have created value for shareholders.
Via
The Motley Fool
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
May 26, 2023
Benzinga
Via
Benzinga
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
May 26, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
May 26, 2023
Via
Benzinga
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
May 25, 2023
From
AstraZeneca
Via
Business Wire
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
May 24, 2023
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ: NVDA)...
Via
Benzinga
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
May 24, 2023
Via
Benzinga
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
May 23, 2023
From
AstraZeneca
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
May 23, 2023
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.